login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ORAGENICS INC (OGEN) Stock News
USA
- NYSEARCA:OGEN -
US6840236094
-
Common Stock
1.39
USD
+0.02 (+1.46%)
Last: 10/8/2025, 8:06:51 PM
1.39
USD
0 (0%)
Pre-Market:
10/9/2025, 4:37:06 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
OGEN Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Oragenics
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
2 months ago - By: Oragenics
Oragenics Q2 2025 Shareholder Update
3 months ago - By: Oragenics
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
3 months ago - By: Benzinga
- Mentions:
APDN
INNV
ARTL
NDRA
...
12 Health Care Stocks Moving In Monday's After-Market Session
3 months ago - By: Oragenics
Oragenics Completes Approximately $16.5 Million Offering
3 months ago - By: Benzinga
- Mentions:
CNC
EQ
DBVT
PLUR
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
3 months ago - By: Oragenics
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
4 months ago - By: Oragenics
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
5 months ago - By: Oragenics
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
5 months ago - By: Oragenics
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Please enable JavaScript to continue using this application.